Evidence Table D-43. Length of intensive care unit stay outcomes for studies comparing interventions to treat delirium

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Median (IQR) days, intervention group | Median (IQR), days, control group | Measure of association (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Haloperidol (Planned dose: 5 Median dose: 15 (10.8-17), 35 | Placebo (Planned dose: 5ml), 36 | Oral | Length of stay, days in ICU | 11.7 (4.6 to 15.7) | 7.3 (4.7 to 12.3) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Haloperidol (Mean dose: 11mg Dose range: 2.5-20mg), 192 | Placebo (Not reported), 184 | Intravenous | Days to ICU discharge | 5 (3 to 13) | 5 (3 to 14) | Hazard ratio 0.95 (95% CI: 0.81 to 1.12), p=Not reported |
| Page, 2013[10](#_ENREF_10), [27](#_ENREF_27) | ICU patients needing MV within 72 hours of admission were enrolled | Haloperidol (Planned dose: 2.5mg), 50 | Placebo (Planned dose: 0.5ml), 52 | Intravenous | Length of critical care stay, excluding patients who died in ICU | 9.5 (5 to 14) | 9 (5 to 18) | Mean difference -1.45 (95% CI: -5.42 to 2.52), p=0.47 |
| Second-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| Devlin, 2010[26](#_ENREF_26) | Patients admitted to Medical & Surgical ICU with delirium. | Quetiapine (Mean dose: 50 Median dose: 110 (88-191 IQR) Max dose: 200 Dose range: 50 to 200mg), 18 | Placebo (Mean dose: 50 Median dose: 210 (116 - 293) Max dose: 200mg), 18 | Either orally or NG tube | Duration of intensive care unit stay, days | 16 (10 to 22) | 16 (13 to 32) |   |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Ziprasidone (Planned dose: 40 Median dose: 113 (81-140), 30 | Placebo (Planned dose: 5ml), 36 | Oral | Length of stay, days in ICU | 9.6 (3.8 to 14.5) | 7.3 (4.7 to 12.3) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Ziprasidone (Mean dose: 20mg Dose range: 5.0-40mg), 190 | Placebo (Not reported), 184 | Intravenous | Days to ICU discharge | 6 (3 to 10) | 5 (3 to 14) | Hazard ratio 1.02 (95% CI: 0.88 to 1.17), p=Not reported |

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Median (IQR) days, intervention group | Median (IQR), days, control group | Measure of association (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. second-generation antipsychotic |  |  |  |  |  |  |  |  |
| Girard, 2010[4](#_ENREF_4) | > 18 years MV medical and surgical ICU patients | Ziprasidone (Planned dose: 40 Median dose: 113 (81-140), 30 | Haloperidol (Planned dose: 5 Median dose: 15 (10.8-17), 35 | Oral | Length of stay, days in ICU | 9.6 (3.8 to 14.5) | 11.7 (4.6 to 15.7) |   |
| Girard, 2018[29](#_ENREF_29) | Patients over 18 years of age in the medical or surgical ICU, with delirium | Ziprasidone (Mean dose: 20mg Dose range: 5.0-40mg), 190 | Haloperidol (Mean dose: 11mg Dose range: 2.5-20mg), 192 | Intravenous | Days to ICU discharge | 6 (3 to 10) | 5 (3 to 13) |   |
| First-generation antipsychotic vs. other |  |  |  |  |  |  |  |  |
| Atalan, 2013[18](#_ENREF_18) | Post cardiac surgery patients with hyperactive type delirium | Morphine sulfate (Max dose: 20mg), 27 | Haloperidol (Max dose: 20mg), 26 | Intramuscular | ICU time (d) | Mean: 2.85 (SD: 1.48) | Mean: 3.31 (SD: 2.32) |   |

CI=confidence interval; ICU=intensive care unit; ICU=intensive care unit; IQR=interquartile range; mg=milligram; ml=milliliter; MV=mechanical ventilation; n=sample size; NG=nadogastric tube; p=p-value; SD=standard deviation